Market Intelligence, Clinical Progress, and High-Purity Reagents for Centrosome-Targeted Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for FAM110A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FAM110A Recombinant Protein (Full-length & domain truncation variants). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed. | View FAM110A Products |
| Gene Delivery | FAM110A Promise-ORF / Lentivirus. Full-length ORF with GFP fusion options. Preserves centrosome targeting domain (aa 1-80). | View FAM110A Products |
| Benchmark Antibody | Anti-FAM110A Antibody. Recombinant positive control for expression analysis; also suitable for ICC/IF and Co-IP. | View FAM110A Products |
| Validator | FAM110A siRNA Set (3 unique sequences). For knockdown verification and specificity controls. | View FAM110A Products |
| Related Target A | AURKA. Synergistic pathway partner in centrosome maturation and mitotic entry. | View AURKA Products |
| Related Target B | PLK1. Complementary target for mitotic catastrophe induction; potential interaction partner for centrosome maturation and spindle assembly. | View PLK1 Products |
| Related Target C | FAM110B. Paralog with 58% sequence homology; potential resistance bypass mechanism. | View FAM110B Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PROTAC / Small Molecule Binding Assays | Intracellular targets require high-purity full-length or domain-specific recombinant proteins (>95% purity, Sequence Verified). |
| Phenotypic Screening Specificity | Sequence-verified stable cell lines built via Lentivirus; guaranteed native intracellular expression. |
| Centrosome Localization Validation | Lentivirus with GFP fusion options; sequence verified ORF preserves predicted centrosome targeting signal (aa 1-80). |
| Protein-Protein Interaction (PPI) Studies | Full-length FAM110A with native conformation; Endotoxin controlled (<1EU/μg) for sensitive cell-based binding assays. |
| Functional Domain Mapping | Custom truncation mutants available (N-terminal, C-terminal domains); sequence verified by mass spectrometry. |
| Lack of Controls & False Positives | Benchmark antibodies for target engagement tracking; valid sequence-specific siRNA for genetic specificity checks. |
Live FAM110A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Centrosome Biology Research on PubMed
- ➤ Recent Cancer Biology Publications
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
FAM110A has emerged as a critical regulator of centrosome duplication and spindle assembly, with significant overexpression documented in prostate cancer, non-small cell lung cancer (NSCLC), hepatocellular carcinoma, and breast cancer. While still in preclinical stages as a therapeutic target, the growing understanding of centrosome amplification as a cancer hallmark positions FAM110A as a high-value node for targeted protein degradation (PROTAC) and siRNA therapeutic development. The race for FAM110A-targeted therapeutics is currently situated in early discovery and preclinical stages, with major academic institutions and emerging biotech firms focusing on RNA interference (RNAi) and PROTACs. As first-generation mitotic inhibitors (like taxanes) face resistance, the next wave of R&D targets highly specific centrosomal proteins like FAM110A to induce synthetic lethality and mitotic catastrophe with reduced systemic toxicity. Future combination strategies with existing microtubule-targeted agents (e.g., docetaxel) or DNA damage repair inhibitors (e.g., PARP inhibitors) are anticipated to overcome refractory solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Targeted Protein Degraders (PROTAC) | Preclinical Biotech / Academic Consortia | Prostate Cancer, NSCLC, HCC | Ternary Complex Validation (Need High-Purity Recombinant Protein for SPR) |
| RNAi / ASO | Emerging Gene Therapy Companies | Solid Tumors, HCC, NSCLC, Breast Cancer | Knockdown Verification (Need Reliable siRNA Sets & Benchmark Abs) |
| Small Molecule Inhibitors | Early Discovery Pharma | Refractory Malignancies, Breast Cancer | Biochemical Binding Assays (Need strictly sequence-verified WT/Mutant proteins) |